Federation Des Caisses Desjardins Du Quebec Avidity Biosciences, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $18.4 Billion
- Q4 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 165 shares of RNA stock, worth $4,440. This represents 0.0% of its overall portfolio holdings.
Number of Shares
165
Previous 165
-0.0%
Holding current value
$4,440
Previous $7,000
42.86%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
257Shares Held
100MCall Options Held
517KPut Options Held
717K-
Price T Rowe Associates Inc Baltimore, MD11MShares$297 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$254 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$232 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$213 Million3.76% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.5MShares$202 Million3.18% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.4B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...